Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 349

1.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic MRI.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2017 Sep 12. pii: S0022-5347(17)77497-6. doi: 10.1016/j.juro.2017.09.033. [Epub ahead of print]

PMID:
28916273
2.

Environmental determinants of Vibrio parahaemolyticus in the Chesapeake Bay.

Davis BJK, Jacobs JM, Davis MF, Schwab KJ, DePaola A, Curriero FC.

Appl Environ Microbiol. 2017 Aug 25. pii: AEM.01147-17. doi: 10.1128/AEM.01147-17. [Epub ahead of print]

PMID:
28842541
3.

ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Expert Panel on Radiation Oncology-Prostate:, Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2016 Oct 20;2(1):62-84. doi: 10.1016/j.adro.2016.10.002. eCollection 2017 Jan-Mar. Review. No abstract available.

4.

Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis.

Schnakenberg Martin AM, Bonfils KA, Davis BJ, Smith EA, Schuder K, Lysaker PH.

Schizophr Res Cogn. 2016 Oct 10;6:15-21. doi: 10.1016/j.scog.2016.09.001. eCollection 2016 Dec.

5.

The evolution of brachytherapy for prostate cancer.

Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, Morton GC, Horwitz EM.

Nat Rev Urol. 2017 Jun 30;14(7):415-439. doi: 10.1038/nrurol.2017.76. Review.

PMID:
28664931
6.

Sternum First, Perhaps Pelvis Later.

Davis BJ, Park SS.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):496. doi: 10.1016/j.ijrobp.2017.04.020. No abstract available.

PMID:
28581389
7.

Brachytherapy in the Management of Prostate Cancer.

Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R.

Surg Oncol Clin N Am. 2017 Jul;26(3):491-513. doi: 10.1016/j.soc.2017.01.008. Epub 2017 May 11. Review.

PMID:
28576185
8.

Renal Mass and Localized Renal Cancer: AUA Guideline.

Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM.

J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.

PMID:
28479239
9.

ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.

Expert Panel on Urologic Imaging:, Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, Froemming AT, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Verma S, Wang CL, Remer EM, Eberhardt SC.

J Am Coll Radiol. 2017 May;14(5S):S245-S257. doi: 10.1016/j.jacr.2017.02.026.

PMID:
28473080
10.

Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption.

Marcus DJ, Henderson-Redmond AN, Gonek M, Zee ML, Farnsworth JC, Amin RA, Andrews MJ, Davis BJ, Mackie K, Morgan DJ.

PLoS One. 2017 Apr 20;12(4):e0174826. doi: 10.1371/journal.pone.0174826. eCollection 2017.

11.

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK.

Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952.

12.

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535. doi: 10.1016/j.ijrobp.2016.11.014. Epub 2016 Nov 17.

PMID:
28126302
13.

Feasibility of reduced-dose three-dimensional/four-dimensional-digital subtraction angiogram using a weighted edge preserving filter.

Oberstar EL, Speidel MA, Davis BJ, Strother CM, Mistretta CA.

J Med Imaging (Bellingham). 2017 Jan;4(1):013501. doi: 10.1117/1.JMI.4.1.013501. Epub 2017 Jan 11.

PMID:
28097212
14.

ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer.

McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ; Expert Panel on Radiation OncologyProstate.

Am J Clin Oncol. 2017 Feb;40(1):1-10. doi: 10.1097/COC.0000000000000354.

PMID:
28059930
15.

ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.

Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N.

Brachytherapy. 2017 Mar - Apr;16(2):266-276. doi: 10.1016/j.brachy.2016.10.002. Epub 2016 Dec 7.

PMID:
27964905
17.

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.

Jethwa KR, Furutani KM, Mynderse LA, Wilson TM, Choo R, King BF, Bergstralh E, Davis BJ.

J Contemp Brachytherapy. 2016 Oct;8(5):371-378. Epub 2016 Nov 4.

18.

Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.

Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED.

Eur Urol. 2017 Mar;71(3):340-348. doi: 10.1016/j.eururo.2016.08.055. Epub 2016 Sep 3.

PMID:
27597240
19.

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N.

Lancet Oncol. 2016 Oct;17(10):1435-1444. doi: 10.1016/S1470-2045(16)30227-3. Epub 2016 Aug 27.

PMID:
27575027
20.

Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by Day 0 fluoroscopy and 4-month postimplant pelvic x-ray.

Birckhead BJ, Fossum CC, Deufel CL, Furutani KM, Merrell KW, Schueler BA, Mynderse LA, Choo R, Davis BJ.

Brachytherapy. 2016 Nov - Dec;15(6):714-721. doi: 10.1016/j.brachy.2016.07.004. Epub 2016 Aug 16.

PMID:
27542893

Supplemental Content

Loading ...
Support Center